FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 546 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Cross-Border Network of European Specialists Provides New Treatment Options For Women... June 17, 2024 How to Support a Spouse or Partner During Cancer Treatment by... April 20, 2021 Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival December 7, 2018 Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials June 29, 2020 Load more HOT NEWS EMA Recommends Extension of Indications for Amivantamab ESMO Congress 2023, 20-24 October 2023 Madrid, Spain Mohs Surgery for Skin Cancer: What to Know and What to... FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic...
